We are live on ! Find out more
ATOS icon

Atossa Therapeutics
ATOS

10 hedge funds and large institutions have $285K invested in Atossa Therapeutics in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

38% more capital invested

Capital invested by funds: $207K → $285K (+$78K)

11% more funds holding

Funds holding: 9 → 10 (+1)

0.03% more ownership

Funds ownership: 0% → 0.03% (+0.03%)

Holders
10
Holders Change
+1
Holders Change %
+11.11%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$85.7K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$68.9K
3
VKH
Virtu KCG Holdings
New York
+$32.4K
4
Wells Fargo
Wells Fargo
California
+$1.25K
5
Deutsche Bank
Deutsche Bank
Germany
+$624

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$8.73K

ATOS Hedge Fund Activity: Q4 2016 in Review

10 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2016, worth a combined $285K — up 38% from $207K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ATOS positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $85.7K. The largest seller was UBS Group, exiting entirely with an estimated $8.73K sold.

  • 10 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2016, up from 9 in Q3 2016.
  • Funds reported $285K of Atossa Therapeutics stock for Q4 2016, up 38% quarter-over-quarter.
  • 2 funds opened new Atossa Therapeutics positions in Q4 2016 and 1 closed out, a net change of +1 holder.
  • The largest Atossa Therapeutics buyer in Q4 2016 was Renaissance Technologies, an estimated $85.7K added.
  • The largest Atossa Therapeutics seller in Q4 2016 was UBS Group, an estimated $8.73K sold.

Based on aggregated 13F filings for Q4 2016.